Article Per Year (5 Year)
p-Index From 2021 - 2026
1.197
P-Index
This Author published in this journals
All Journal Pharmaciana: Jurnal Kefarmasian Jurnal Ilmiah Medicamento Borneo Journal of Pharmacy
Meriyani, Herleeyana
Unknown Affiliation
Health Professions Medicine & Pharmacology Public Health

Published : 22 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 22 Documents
Search

 1   2   3 
ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN TERAPI INSULIN DAN INSULIN KOMBINASI PADA PASIEN DIABETES MELLITUS TIPE II RAWAT JALAN DI RSUP SANGLAH Putra, I Made Agus Sunadi; Udayani, Ni Nyoman Wahyu; Meriyani, Herleeyana
Jurnal Ilmiah Medicamento Vol 3 No 2 (2017): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v3i2.907

Abstract

Diabetes mellitus (DM) tipe 2 merupakan suatu kelompok penyakit metabolik dengan karakteristik hiperglikemia yang terjadi karena resistensi insulin disertai defisiensi insulin relatif. Bervariasinya penggunaan terapi insulin tunggal atau kombinasi insulin dengan antidiabetik oral pada pasien DM tipe 2 dengan kontrol glukosa darah yang belum adekuat akan mengakibatkan adanya perbedaan dalam biaya dan efektivitas terapinya. Penelitian ini merupakan penelitian deskriptif yang dilakukan secara prospektif dan studi follow up dari bulan Mei sampai dengan Agustus 2017. Subyek penelitian adalah 70 pasien DM tipe 2 yang memenuhi kriteria inklusi. Data dianalisis untuk mengetahui jenis terapi dan biaya medis langsung. Efektivitas terapi dinilai dari tercapainya target HbA1c <7% setelah follow up 3 bulan terapi dan tidak munculnya efek samping obat (hipoglikemia). Metode ACER digunakan untuk menganalisa jenis terapi insulin yang paling cost-effective. Berdasarkan data yang didapatkan dari rekam medis RSUP Sanglah Denpasar, jumlah pasien DM tipe 2 lebih banyak diderita oleh laki-laki yaitu 47 orang dengan presentase 67,14%, umur >45 tahun yaitu 63 orang dengan presentase 90,00%. Jumlah pasien DM tipe 2 yang mencapai target GDP yaitu 34 orang dengan presentase 48,57%, mencapai target HbA1C yaitu 60 orang dengan presentase 85%. Jumlah pasien DM tipe 2 lebih banyak yang menggunakan terapi kombinasi insulin aspart dengan insulin glargine yaitu 42 orang dengan presentase 60%. Total biaya medis langsung yang menunjukkan jumlah paling murah adalah penggunaan terapi insulin glargine dengan metformin yaitu Rp. 274.880,00. Efektivitas terapi yang lebih besar ditunjukkan oleh jenis terapi kombinasi insulin glargine dengan metformin yaitu 63,63%. Efektivitas biaya yang lebih rendah ditunjukkan oleh jenis terapi kombinasi insulin glargine dengan metformin yaitu Rp. 4,32 persentase efektivitas.
AKTIVITAS ANTIOKSIDAN EKSTRAK ETANOL DAUN KELADI TIKUS (Typhonium flagelliforme) DENGAN METODE DPPH (1,1- Diphenyl-2-Picryhidrazyl) Adrianta, Ketut Agus; Udayani, Ni Nyoman Wahyu; Meriyani, Herleeyana
Jurnal Ilmiah Medicamento Vol 3 No 1 (2017): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v3i1.1047

Abstract

Keladi tikus (Typhonium flagelliforme) suku Araceae merupakan salah satu tanaman obat Indonesia, yang diduga berkhasiat membunuh atau menghambat pertumbuhan sel kanker, menekan efek negatif dari proses pengobatan modern (khemoterapi) seperti rambut rontok, nafsu makan hilang, rasa mual dan rasa nyeri di tubuh, bersifat antivirus dan anti bakteri. Untuk itu perlu dilakukan penelitian dengan menguji aktivitas antioksidan ekstrak etanol daun keladi tikus yang terdapat di Sidakarya, Denpasar, Bali. Pengujian aktivitas antioksidan dilakukan terhadap ekstrak etanol daun keladi tikus dilakukan dengan metode penangkapan radikal DPPH. Pengujian ini diawali dengan penyiapan sampel, kemudian diekstraksi dengan metode ultrasonik dengan pelarut etanol. Uji aktivitas antioksidan diukur dengan spektrofotometer UV-Vis. Hasil persentase peredaman diplotkan untuk mendapat kurva regresi linier. Sehingga didapat persamaan y = bx + a dan nilai IC50 dihitung dari persamaan regresi linier yang diperoleh. Uji aktivitas antioksidan etanol daun keladi tikus diukur pada panjang gelombang 518 nm. Dari kurva regresi diperoleh persamaan regresi adalah y = 0.527x + 9.891 dan R2= 0,985. Nilai IC50 yang diperoleh sebesar 76.10 ppm. Antioksidan yang terkandung dalam ekstrak etanol daun keladi tikus dikatagorikan dalam antioksidan kuat.
PERBEDAAN EFEKTIVITAS PENGGUNAAN OBAT ANTIDIABETIK ORAL TUNGGAL DENGAN KOMBINASI PADA PASIEN DM TIPE 2 DI UPT. PUSKESMAS DAWAN II KABUPATEN KLUNGKUNG PERIODE NOVEMBER 2015-PEBRUARI 2016 Udayani, Ni Nyoman Wahyu; Meriyani, Herleeyana
Jurnal Ilmiah Medicamento Vol 2 No 2 (2016): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v2i2.1096

Abstract

DM tipe 2 merupakan penyakit progresif dengan karakteristik penurunan fungsi sel beta pankreas. Penelitian ini bertujuan untuk mengetahui perbedaan efektivitas penggunaan obat antidiabetik oral tunggal dengan kombinasi pada pasien DM tipe 2 di UPT. Puskesmas Dawan II Kabupaten Klungkung. Penelitian ini merupakan penelitian cross sectional dan pengumpulan data dilakukan secara prospektif. Penelitian dilakukan dari bulan November 2015-Pebruari 2016 di UPT. Puskesmas Dawan II Kabupaten Klungkung. Penelitian dilakukan terhadap 25 subjek penelitian dengan terapi tunggal glibenklamid dan 25 subjek penelitian dengan terapi kombinasi glibenklamid dengan metformin. Hasilnya menunjukkan bahwa tidak terdapat perbedaan bermakna dari efektivitas penggunaan obat antidiabetik oral tunggal glibenklamid dengan kombinasi glibenklamid dengan metformin pada pasien DM tipe 2 di UPT. Puskesmas Dawan II Kabupaten Klungkung periode November 2015-Pebruari 2016 (p = 0.114).
EFEKTIVITAS TERAPI PNEUMONIA PADA PASIEN PEDIATRIK DI RUMAH SAKIT UMUM PUSAT SANGLAH DENPASAR DITINJAU DARI PARAMETER RESPIRATION RATE Meriyani, Herleeyana; Megawati, Fitria; Udayani, Ni Nyoman Wahyu
Jurnal Ilmiah Medicamento Vol 2 No 2 (2016): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v2i2.1102

Abstract

Pneumonia merupakan salah satu penyakit yang masih banyak dijumpai pada Negara berkembang seperti Indonesia. Penelitian ini bertujuan untuk mengetahui efektivitas terapi pneumonia pada pasien pediatrik dengan diagnosa pneumonia yang dirawat inap di RSUP Sanglah periode tahun 2014- 2015 ditinjau dari parameter respiration rate (RR) serta melihat pengaruh penggunaan jenis antibiotik (tunggal/kombinasi) dan terapi tambahan terhadap konversi nilai respiration rate (RR). Desain/jenis penelitian ini merupakan penelitian studi cross-sectinal (potong lintang) dengan pengambilan data secara retrospektif terhadap rekam medis pasien. Data yang diperoleh akan dianalisa secara statistika dengan taraf kepercayaan 95%. Untuk menilai efektivitas terapi pneumonia dilakukan dengan membandingkan Respiration Rate (RR) sebelum dan sesudah terapi. Teknik sampling yang digunakan dalam penelitian ini adalah teknik purposive sampling. Pasien anak degan pneumonia yang menjadi sampel dalam penelitian ini yaitu sebanyak 119 pasien. Berdasarkan analisa statistika Wilcoxon diperoleh bahwa terdapat perbedaan bermakna antara nilai RR sebelum dan sesudah terapi (p<0.05). berdasarkan analisa statistika Chi-Square diperoleh bahwa jenis antibiotik tunggal maupun kombinasi dan penggunaan bronkodilator tidak berpengaruh terhadap konversi nilai RR (p>0.05), sedangkan penggunaan kortikosteroid berpengaruh terhadap konversi nilai RR (p<0.05).
Kualitas Penggunaan Antibiotik pada Pasien Community-Acquired Pneumonia di Salah Satu Rumah Sakit di Bali Meriyani, Herleeyana; Sanjaya, Dwi Arymbhi; Juanita, Rr. Asih; Siada, Nyoman Budiartha
Jurnal Ilmiah Medicamento Vol 10 No 1 (2024): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v10i1.7592

Abstract

Community-acquired pneumonia (CAP) is an infectious disease with high morbidity and mortality rates. Antibiotics are essential therapies for bacterial CAP. The use of antibiotics is a critical point in CAP treatment. Inappropriate use of antibiotics leads to antibiotic resistance. The study aimed to evaluate the proper use of antibiotics in CAP patients and identify the relationship between the appropriate use of antibiotics and the use of single/combined antibiotics with prolonged length of stay. This study was a cross-sectional study with retrospective data collection at a general hospital in Bali. Evaluation of the proper use of antibiotics was done using the Gyssens algorithm. The relationship between the appropriate use of antibiotics and the type of antibiotic (single/combined) with the length of stay was carried out using the Chi-square test with a 95% confidence interval. There were 151 CAP patients as samples in this study consisting of 55.63% men and 44.37% women with a median age of 60 years (18-89). The appropriate use of antibiotics was 17.88%, while 82.18% of the total antibiotic use was inappropriate. The Inappropriate use of antibiotics in category IIA (incorrect dosage) is 3.97%, category IIIB (inappropriate interval) is 4.64%, category IVC (cheaper alternative antibiotics were available) is 41.72%, and category V (no indication) is 37.79%. There is no significant relationship between the appropriate use of antibiotics and prolonged LOS [p>0.05; OR: 1.132 (CI: 0.466-2.746)] however the use of antibiotics (single or in combination) significantly affects the prolonged LOS [p<0.05; OR: 0.027 (CI: 0.004-0.204)].
Studi Retrospektif Penggunaan Antibiotik pada Pasien Covid-19 dengan Pneumonia di Rumah Sakit “X” Provinsi Bali, Indonesia Siada, Nyoman Budiartha; Juanita, Rr Asih; Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana
Jurnal Ilmiah Medicamento Vol 10 No 1 (2024): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v10i1.7637

Abstract

COVID-19 with bacterial pneumonia co-infection is a condition with bacteria present in COVID-19 patients. The prevalence of bacterial co-infection in COVID-19 patients ranges from 12.4%–50%. This study aims to determine the relationship between the appropriate use of antibiotics and the severity of inpatients with COVID-19 and pneumonia co-infection at Hospital "X" Bali Province, Indonesia. This research is an observational study with a cross-sectional approach. Data collection was carried out retrospectively on medical record data of COVID-19 inpatients with pneumonia co-infection at Hospital "X" Bali Province, Indonesia for the period January - December 2021. The sampling technique used total sampling according to inclusion and exclusion criteria. Appropriate use of antibiotics antibiotic was analyzed using Pharmaceutical Care Network Europe (PCNE) version 9.1. The patient severity index was an assessment based on the Pneumonia Severity Index (PSI) score. The relationship between the appropriate use of antibiotics and the severity of inpatients with COVID-19 and pneumonia co-infection was analyzed using Fisher's test. Of the 80 COVID-19 inpatients with pneumonia co-infection, 90% experienced inappropriate use of antibiotics. Fisher's test results showed that there was no significant relationship between the appropriate use of antibiotics and the severity of inpatients with COVID-19 and pneumonia co-infection at Hospital "X" Bali Province, Indonesia (p > 0.05).
AKTIVITAS ANTIOKSIDAN EKSTRAK ETANOL DAUN KELADI TIKUS (Typhonium flagelliforme) DENGAN METODE DPPH (1,1- Diphenyl-2-Picryhidrazyl) Adrianta, Ketut Agus; Udayani, Ni Nyoman Wahyu; Meriyani, Herleeyana
Jurnal Ilmiah Medicamento Vol 3 No 1 (2017): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v3i1.1047

Abstract

Keladi tikus (Typhonium flagelliforme) suku Araceae merupakan salah satu tanaman obat Indonesia, yang diduga berkhasiat membunuh atau menghambat pertumbuhan sel kanker, menekan efek negatif dari proses pengobatan modern (khemoterapi) seperti rambut rontok, nafsu makan hilang, rasa mual dan rasa nyeri di tubuh, bersifat antivirus dan anti bakteri. Untuk itu perlu dilakukan penelitian dengan menguji aktivitas antioksidan ekstrak etanol daun keladi tikus yang terdapat di Sidakarya, Denpasar, Bali. Pengujian aktivitas antioksidan dilakukan terhadap ekstrak etanol daun keladi tikus dilakukan dengan metode penangkapan radikal DPPH. Pengujian ini diawali dengan penyiapan sampel, kemudian diekstraksi dengan metode ultrasonik dengan pelarut etanol. Uji aktivitas antioksidan diukur dengan spektrofotometer UV-Vis. Hasil persentase peredaman diplotkan untuk mendapat kurva regresi linier. Sehingga didapat persamaan y = bx + a dan nilai IC50 dihitung dari persamaan regresi linier yang diperoleh. Uji aktivitas antioksidan etanol daun keladi tikus diukur pada panjang gelombang 518 nm. Dari kurva regresi diperoleh persamaan regresi adalah y = 0.527x + 9.891 dan R2= 0,985. Nilai IC50 yang diperoleh sebesar 76.10 ppm. Antioksidan yang terkandung dalam ekstrak etanol daun keladi tikus dikatagorikan dalam antioksidan kuat.
Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review Meriyani, Herleeyana; Sanjaya, Dwi Arymbhi; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Chusna, Nurul; Ketupapa, Florentina Gabriela
Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v8i1.7913

Abstract

Triple-negative breast cancer is an aggressive and poor prognosis subtype of breast cancer. Eribulin has shown promise in the treatment of metastatic triple-negative breast cancer (mTNBC). This review aimed to provide a specific description, evidence, and discussion of the efficacy and safety of eribulin both as monotherapy and in combination with another agent in patients with mTNBC. The search was conducted in five databases (PubMed, ScienceDirect, PLoS One, Wiley Online Library, and Cochrane Library) towards published articles during the 2013-2023 period. A total of 237 articles were identified. After removing 69 duplicates, 168 articles underwent the screening process and 10 articles met the research criteria. Eribulin monotherapy effectiveness profile includes: overall survival (10.8-17.6 months), progression-free survival (2.8-3.2 months), partial response (21.0%-58.7%), progressive disease (15.5% -47.0%), and stable disease (28.8%-32%). However, there were no cases of complete response. Combination of eribulin with other agents' effectiveness profiles includes: overall survival (8.3-14.5 months), PFS (2.6-8.1 months), partial response (31.8-76.0%), complete response (2.4-8%), progressive disease (8.0-28%), and stable disease (8.0-52.3%). Eribulin monotherapy's safety profile is similar to that of combination therapy. No grade 5 adverse event was reported during monotherapy or in combination with other agents. The grade 4 adverse events reported are neutropenia, leukopenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, vomiting, dyspnea, back pain, arthralgia, febrile neutropenia, dyspnea, constipation, general physical health deterioration, alopecia. The all-grade adverse events with a percentage above 50% are neutropenia, leukopenia, thrombocytopenia, asthenia, alopecia, elevated AST, elevated ALT, hand-foot syndrome, fatigue, anemia, peripheral neuropathy, oral mucositis, and nausea.
Cross-resistance to antibiotics of Escherichia coli in the inpatient installation of general regional hospital “X” Bali, Indonesia Mahaputra, I Putu Yudistira; Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr Asih; Siada, Nyoman Budiartha; Kamalia, Made Gek Adisti; Adrianta, Ketut Agus; Noviani, Lusy
Pharmaciana Vol. 15 No. 1 (2025): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v15i1.29209

Abstract

Escherichia coli (E. coli) is a critical-priority group of MDR bacteria and its spread can occur in hospital inpatient settings. Several studies showed that antibiotics consumption for inpatients can cause E. coli resistance to other antibiotics called cross-resistance. The aim of this study to determine the cross-resistance in E. coli to antibiotics in the inpatient installation of the regional general hospital "X" in Bali, Indonesia by analyzing the relationship between the antibiotic consumption and the percentage of antibiotic resistance of E. coli. This research is an ecological study with the independent variable is the antibiotics consumption defined as defined daily doses/100 bed-days and the dependent variable is the percentage of E. coli resistance during 2017-2020. The correlation between the level of antibiotic consumption and the percentage of E. coli resistance to antibiotics was analyzed using the Pearson correlation tests. The results showed that the consumption of tetracycline had a significant correlation with increased resistance of E. coli to meropenem and piperacillin-tazobactam (r=0.8-1.0; p<0.05). This showed that there is cross-resistance in E. coli. This incident is associated with selective pressure, horizontal and vertical gene transfer in E. coli. The consumption of tetracycline, apart from inducing the production of the tet gene which is the cause of resistance to tetracycline, can also induce the production of resistance genes to broad-spectrum beta-lactam antibiotics such as piperacillin-tazobactam and meropenem.
Efektivitas dan Efek Samping pada Terapi Multi-Drug-Resistant Tuberculosis (MDR-TB): Kajian Literatur Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Noviani, Lusy
Jurnal Ilmiah Medicamento Vol 11 No 1 (2025): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v11i1.9685

Abstract

Multi-drug-resistant tuberculosis (MDR-TB) leads to a reduced cure rate for tuberculosis treatment. The global number of MDR-TB cases remained relatively stable between 2015 and 2020 but increased in 2021. In 2020, the World Health Organization (WHO) estimated 437,000 MDR-TB cases worldwide, which rose to 450,000 cases in 2021. Various treatment regimens recommended by the WHO require a review of the literature on the efficacy and side effects of drug use in MDR-TB. This review aims to provide updated information that can be used as a reference for the early identification and management of side effects. The article was a narrative review that collected and analyzed information from various international articles on databases such as PubMed, PlosOne, and ScienceDirect from January 2014 to June 2024. A total of six relevant articles were synthesized from 609 articles. The effectiveness of MDR-TB therapy with WHO-recommended drugs has shown a high cure rate (cured>50%). The incidence of side effects in MDR-TB therapy is smaller compared to the effectiveness of treatment. However, a study conducted at Wuhan Jinyintan Hospital in China from July 2019 to December 2020 showed that all study subjects experienced side effects. This included nausea and vomiting from protionamide, gatifloxacin, and ethambutol; hyperuricemia from pyrazinamide, and hyperpigmentation from clofazimine. It is recommended that a therapy regimen be selected based on culture test results, patient conditions, and drug availability in each country.
Co-Authors Chusna, Nurul Ciptawati, Ni Wayan Dwi Arymbhi Sanjaya Fredinan Yulianda Kamalia, Made Gek Adisti Ketupapa, Florentina Gabriela Ketut Agus Adrianta Mahaputra, I Putu Yudistira Mahaputra, Yudistira Megawati, Fitria Ni Made Dharma Shantini Suena Ni Nyoman Wahyu Udayani Ni Putu Udayana Antari Noviani, Lusy Nyoman Budiartha Siada Putra, I Made Agus Sunadi RR. Asih Juanita SARTIKAWATI, NI KADEK AYU Wardani, I Gusti Agung Ayu Kusuma Wintariani, Ni Putu